Evaluation of Protoporphyrin IX Formation in Healthy Skin Following Topical Application of 2 Methyl Aminolevulinate Creams: A Randomized, Investigator-Masked Pilot Study

The primary objective of this study is to establish the experimental conditions and select the criteria necessary to compare the topical application of two **methyl aminolevulinate** creams. This evaluation focuses on the formation of **protoporphyrin IX** in the skin of healthy subjects. Understanding the conditions that optimize protoporphyrin IX formation is clinically relevant as it may inform future therapeutic applications and enhance the efficacy of treatments involving methyl aminolevulinate. No secondary objectives are specified for this study.

The clinical trial involves **healthy subjects** with no specific medical conditions. The study population includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected without specific lifestyle considerations such as diet or physical activity being highlighted. The trial does not specify any principal inclusion criteria, and the main objective of the trial is not disclosed.

The clinical trial is designed as a **randomized**, investigator-masked pilot study aimed at establishing experimental conditions and selecting criteria to compare the topical application of two methyl aminolevulinate creams. The study will evaluate the formation of **protoporphyrin IX** in the skin of healthy subjects. The trial is categorized as a Phase 3 study and is expected to commence recruitment on September 2, 2024, with an estimated completion date of September 30, 2024. The trial will involve a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants will undergo a series of follow-up visits to monitor the effects of the treatment and ensure adherence to the study protocol. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to evaluate the primary and secondary endpoints of the trial.

The expected duration of participant involvement will be determined by the study protocol, with specific timelines outlined for each visit. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events, or withdrawal of consent by the participant. The trial will adhere to rigorous scientific and ethical standards to ensure the validity and reliability of the results. The study's design and procedures are structured to minimize bias and maximize the accuracy of the findings, contributing valuable data to the field of dermatological research.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 2, 2024, with an estimated end date of September 30, 2024. The efficacy assessment will be conducted in accordance with the trial's protocol, which is aligned with the standards for Phase 3 clinical trials. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and schedule for measuring, collecting, and analyzing these parameters, are not detailed in the provided data. The trial will adhere to the regulatory and ethical guidelines applicable to clinical research, ensuring the integrity and reliability of the efficacy data collected throughout the study duration.